This study will randomized hematology oncology patients with active diarrhea and a NAAT
positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo. The
study is designed to include 30 patients (15 per arm).
Outcomes will include C. difficile load using qPCR, VRE loads, structural and functional
microbiome changes and frequency of bowel movements. All endpoints will be measured at
several time points including days 0, 14, 21 and 90.